Tokyo, July 15 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058459) titled 'Comparison of the Effectiveness of CDK4/6 Inhibitors as First-Line or Later-Line Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Recurrent Breast Cancer' on July 15.
Study Type:
Observational
Primary Sponsor:
Institute - Fukui University
Condition:
Condition - Breast Cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - By evaluating the effectiveness of one or two reimbursed CDK4/6 inhibitors, as well as treatments administered before and after their use, this study aims to provide evidence that could greatly contribute to treatment decision-making for patients with hormone receptor-positive, HER2-negative metastatic or recurrent breast cancer.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 20
years-old
=
Gender - Male and Female
Key inclusion criteria - 1.Patients with hormone receptor-positive, HER2-negative metastatic or recurrent breast cancer who received treatment with a single CDK4/6 inhibitor (palbociclib or abemaciclib) between March 1, 2018 and November 30, 2019.
2.Patients with hormone receptor-positive, HER2-negative metastatic or recurrent breast cancer who received two different CDK4/6 inhibitors at different treatment timings between March 1, 2018 and November 30, 2019.
Key exclusion criteria - None
Target Size - 66
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2025 Year 05 Month 19 Day
Date of IRB - 2025 Year 05 Month 09 Day
Anticipated trial start date - 2025 Year 05 Month 19 Day
Last follow-up date - 2025 Year 11 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066847
Disclaimer: Curated by HT Syndication.
